H.C. Wainwright says NCCN addition could positively impact Puma’s Nerlynx sales

H.C. Wainwright analyst Edward White notes Puma Biotechnology (PBYI) announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Cervical Cancer were updated to include monotherapy Nerlynx for use as a second line or subsequent therapy for recurrent or metastatic disease as an option for patients with HER2-mutated tumors with a designation of Category 2A. Nerlynx is Puma’s marketed irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1, HER2, and HER4. Wainwright believes the NCCN addition could provide a positive impact to sales. The firm estimates net Nerlynx sales of $46.4M in Q4 2024, and net product sales of $187.2M 2024 and $195.3M in 2025. Wainwright has a Buy rating on the shares with a price target of $7.